Open Access

S100A11 promotes human pancreatic cancer PANC‑1 cell proliferation and is involved in the PI3K/AKT signaling pathway

  • Authors:
    • Mingbing Xiao
    • Tao Li
    • Yifei Ji
    • Feng Jiang
    • Wenkai Ni
    • Jing Zhu
    • Baijun Bao
    • Cuihua Lu
    • Runzhou Ni
  • View Affiliations

  • Published online on: October 31, 2017     https://doi.org/10.3892/ol.2017.7295
  • Pages:175-182
  • Copyright: © Xiao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views
0

Abstract

S100A11, a member of S100 calcium‑binding protein family, is associated with the numerous processes of tumorigenesis and metastasis. In the present study, the role of S100A11, and its possible underlying mechanisms in cell proliferation, apoptosis and cell cycle distribution in human pancreatic cancer were explored. Immunohistochemical analyses of S100A11 and phosphorylated (p)‑AKT serine/threonine kinase (AKT) were performed in 30 resected specimens from patients with pancreatic cancer. PANC‑1 cells were transfected with pcDNA3.1‑S100A11 or treated with 50 µmol/l LY294002 for 48 h. Cell proliferation was determined using a cell counting kit‑8 assay, whereas apoptosis and cell cycle distribution were determined by flow cytometry analysis. The mRNA and protein levels of S100A11, and AKT were determined using semi quantitative reverse transcription‑polymerase chain reaction and western blot analyses, respectively. Pearson correlation analysis revealed that the expression levels of S100A11 and p‑AKT were positively correlated (r, 0.802; P<0.05). Compared with the control group, S100A11 overexpression significantly promoted PANC‑1 cell proliferation and reduced the percentage of early apoptotic cells. Flow cytometric analysis indicated that the proportion of PANC‑1 cells in the S phase was significantly elevated and cell percentage in the G0/G1 phase declined in response to S100A11 overexpression (all P<0.05). S100A11 overexpression also significantly increased AKT mRNA and p‑AKT protein expression levels (both P<0.05). The phosphoinositide 3‑kinase (PI3K) inhibitor, LY294002, significantly inhibited PANC‑1 cell proliferation, promoted apoptosis and caused G1/S phase arrest in PANC‑1 cells (all P<0.05). These findings together suggest that S100A11 promotes the viability and proliferation of human pancreatic cancer PANC‑1 cells through the upregulation of the PI3K/AKT signaling pathway. Thus, S100A11 may be considered as a novel drug target for targeted therapy of pancreatic cancer.

Related Articles

Journal Cover

January 2018
Volume 15 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Xiao, M., Li, T., Ji, Y., Jiang, F., Ni, W., Zhu, J. ... Ni, R. (2018). S100A11 promotes human pancreatic cancer PANC‑1 cell proliferation and is involved in the PI3K/AKT signaling pathway. Oncology Letters, 15, 175-182. https://doi.org/10.3892/ol.2017.7295
MLA
Xiao, M., Li, T., Ji, Y., Jiang, F., Ni, W., Zhu, J., Bao, B., Lu, C., Ni, R."S100A11 promotes human pancreatic cancer PANC‑1 cell proliferation and is involved in the PI3K/AKT signaling pathway". Oncology Letters 15.1 (2018): 175-182.
Chicago
Xiao, M., Li, T., Ji, Y., Jiang, F., Ni, W., Zhu, J., Bao, B., Lu, C., Ni, R."S100A11 promotes human pancreatic cancer PANC‑1 cell proliferation and is involved in the PI3K/AKT signaling pathway". Oncology Letters 15, no. 1 (2018): 175-182. https://doi.org/10.3892/ol.2017.7295